Research update- July 2020
The impact of COVID-19 has been serious and will have long-lasting consequences for medical research in the UK, not least because so much of our medical research is funded by charities.
Supporting Decision Making - REDMAPP Study
The REDMAPP research study aims to develop a decision aid to support parents when their child has relapsed neuroblastoma by first gaining a greater understanding of how parents make a series of repeated treatment-related decisions.
Charities fund new clinical trial
Solving Kids’ Cancer, with Neuroblastoma UK, has awarded a grant of £609,762.40 to enable the SIOPEN High-Risk Neuroblastoma Clinical Trial 2 (HR-NBL2) to open in the UK, it is anticipated to open in early 2021.
Research update - May 2020
The coronavirus pandemic has brought new challenges to our ongoing research programme, as we work with experts worldwide to bring more, better and less toxic treatment to children in the UK and beyond.
Watch brave Kira on Scotland Tonight
Kira Noble, supported by Solving Kids' Cancer throughout her cancer journey, appeared on Scotland Tonight on 13th February as STV followed her latest scan and results.
Grant awarded to identify markers of poor survival in high-risk neuroblastoma
Solving Kids’ Cancer Europe, Solving Kids' Cancer in New York, Oscar Knox Fund, Smiles for Stanley Fund and Merryn Lacy Trust have awarded a grant of $420,000.
Outcome for children in the UK after high-risk neuroblastoma treatment
We explain the recent statement from the UK clinical community.
CCLG statement: Outcome after high-risk neuroblastoma treatment
SIOPEN, the UK National Cancer Research Institute Neuroblastoma Group and the CCLG Neuroblastoma Special Interest Group are committed to further improving the outcome for children with neuroblastoma.
BEACON study opens in Europe
This new clinical trial will be available to children in 40 hospitals across 11 European countries and has been jointly funded by Solving Kids’ Cancer UK and the French charity, Imagine for Margo.
